B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Gao S, Li N, Wang S, et al. Lung cancer in People’s Republic of China. J Thorac Oncol. 2020;15(10):1567–1576. doi:10.1016/j.jtho.2020.04.028
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.11058
   PubMed Web of Science ®Google Scholar
• Azoury SC, Straughan DM, Shukla V. Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety. Curr Cancer Drug Targets. 2015;15(6):452–462. doi:10.2174/156800961506150805145120
   PubMed Web of Science ®Google Scholar
• Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials checkMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733. doi:10.1200/JCO.20.01605
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39. doi:10.1038/s41577-019-0218-4
   PubMed Web of Science ®Google Scholar
• Yuan Y, Adam A, Zhao C, Chen H. Recent advancements in the mechanisms underlying resistance to PD-1/PD-L1 blockade immunotherapy. Cancers. 2021;13(4):663. doi:10.3390/cancers13040663
   PubMed Web of Science ®Google Scholar
• Juarez-Garcia A, Sharma R, Hunger M, Kayaniyil S, Penrod JR, Chouaïd C. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: a systematic literature review. Lung Cancer. 2022;166:205–220. doi:10.1016/j.lungcan.2022.03.008
   PubMed Web of Science ®Google Scholar
• Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol. 2021;10(1). doi:10.1186/s40164-021-00211-8
   PubMed Web of Science ®Google Scholar
• Wojas-Krawczyk K, Kubiatowski T. Imperfect predictors for lung cancer immunotherapy-a field for further research. Front Oncol. 2020;10:568174. doi:10.3389/fonc.2020.568174
   PubMed Web of Science ®Google Scholar
• Büttner R, Longshore JW, López-Ríos F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open. 2019;4(1):e000442. doi:10.1136/esmoopen-2018-000442
   PubMed Web of Science ®Google Scholar
• McGrail DJ, Pilié PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021;32(5):661–672. doi:10.1016/j.annonc.2021.02.006
   PubMed Web of Science ®Google Scholar
• Dal Porto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J. B cell antigen receptor signaling 101. Mol Immunol. 2004;41(6–7):599–613. doi:10.1016/j.molimm.2004.04.008
   PubMed Web of Science ®Google Scholar
• Kim S, Summer W, Miyauchi S, Cohen EE, Califano JA, Sharabi AB. Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clin Cancer Res. 2021;27(22):6075–6082. doi:10.1158/1078-0432.CCR-21-0697
   PubMed Web of Science ®Google Scholar
• Ghosh D, Jiang W, Mukhopadhyay D, Mellins ED. New insights into B cells as antigen presenting cells. Curr Opin Immunol. 2021;70:129–137. doi:10.1016/j.coi.2021.06.003
   PubMed Web of Science ®Google Scholar
• Ye J, Lee PP. B cell receptor signaling strength modulates cancer immunity. J Clin Invest. 2022;132(6):e157665. doi:10.1172/JCI157665
   PubMed Web of Science ®Google Scholar
• Profitós-Pelejà N, Santos JC, Marín-Niebla A, Roué G, Ribeiro ML. Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. Cancers. 2022;14(4):860. doi:10.3390/cancers14040860
   PubMed Web of Science ®Google Scholar
• Taylor J, Wilmore S, Marriot S, et al. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells. Cell Signal. 2022;94:110311. doi:10.1016/j.cellsig.2022.110311
   PubMed Web of Science ®Google Scholar
• Jebaraj BMC, Müller A, Dheenadayalan RP, et al. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. Blood. 2022;139(6):859–875. doi:10.1182/blood.2021011516
   PubMed Web of Science ®Google Scholar
• Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36(7):633–641. doi:10.1200/JCO.2017.75.3384
   PubMed Web of Science ®Google Scholar
• Miao D, Margolis CA, Vokes NI, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018;50(9):1271–1281. doi:10.1038/s41588-018-0200-2
   PubMed Web of Science ®Google Scholar
• Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202–206. doi:10.1038/s41588-018-0312-8
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. doi:10.1093/nar/gkv1507
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740. doi:10.1093/bioinformatics/btr260
   PubMed Web of Science ®Google Scholar
• Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2019;51(2):411–412. doi:10.1016/j.immuni.2019.08.004
   PubMed Web of Science ®Google Scholar
• Luo P, Lin A, Li K, Wei T, Zhang J. DDR pathway alteration, tumor mutation burden, and cisplatin sensitivity in small cell lung cancer: difference detected by whole exome and targeted gene sequencing. J Thorac Oncol. 2019;14(12):e276–e279. doi:10.1016/j.jtho.2019.08.2509
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259. doi:10.1007/978-1-4939-7493-1_12
   PubMedGoogle Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Wang S, He Z, Wang X, Li H, Liu XS. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife. 2019;8:e49020. doi:10.7554/eLife.49020
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao J, Wang G, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78(22):6486–6496. doi:10.1158/0008-5472.CAN-18-1814
   PubMed Web of Science ®Google Scholar
• Teo MY, Seier K, Ostrovnaya I, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36(17):1685–1694. doi:10.1200/JCO.2017.75.7740
   PubMed Web of Science ®Google Scholar
• Dougan M, Dougan SK. Targeting immunotherapy to the tumor microenvironment. J Cell Biochem. 2017;118(10):3049–3054. doi:10.1002/jcb.26005
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhou N, Lin A, et al. ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2021;70(1):137–151. doi:10.1007/s00262-020-02668-8
   PubMed Web of Science ®Google Scholar
• Huang W, Lin A, Luo P, et al. EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma. Cancer Gene Ther. 2021;28(7–8):864–874. doi:10.1038/s41417-020-0207-6
   PubMed Web of Science ®Google Scholar
• Jacquelot N, Pitt JM, Enot DP, et al. Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. Oncoimmunology. 2017;6(8):e1299303. doi:10.1080/2162402X.2017.1299303
   PubMed Web of Science ®Google Scholar
• Reiser J, Banerjee A. Effector, memory, and dysfunctional CD8(+) T cell fates in the antitumor immune response. J Immunol Res. 2016;2016:8941260. doi:10.1155/2016/8941260
   PubMed Web of Science ®Google Scholar
• Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–645. doi:10.1126/science.1251102
   PubMed Web of Science ®Google Scholar
• Cui C, Wang J, Fagerberg E, et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell. 2021;184(25):6101–6118.e13. doi:10.1016/j.cell.2021.11.007
   PubMed Web of Science ®Google Scholar
• Ganesan AP, Johansson M, Ruffell B, et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J Immunol. 2013;191(4). doi:10.4049/jimmunol.1301317
   PubMed Web of Science ®Google Scholar
• Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM. A protective role of mast cells in intestinal tumorigenesis. Carcinogenesis. 2008;29(4):880–886. doi:10.1093/carcin/bgn040
   PubMed Web of Science ®Google Scholar
• Hodges K, Kennedy L, Meng F, Alpini G, Francis H. Mast cells, disease and gastrointestinal cancer: a comprehensive review of recent findings. Transl Gastrointest Cancer. 2012;1(2):138–150.
   PubMedGoogle Scholar
• Somasundaram R, Connelly T, Choi R, et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021;12(1). doi:10.1038/s41467-020-20600-7
   PubMed Web of Science ®Google Scholar
• Liu J, Zhang Y, Zhao J, et al. Mast cell: insight into remodeling a tumor microenvironment. Cancer Metastasis Rev. 2011;30(2):177–184. doi:10.1007/s10555-011-9276-1
   PubMed Web of Science ®Google Scholar
• Lin A, Zhang H, Meng H, et al. TNF-alpha pathway alternation predicts survival of immune checkpoint inhibitors in non-small cell lung cancer. Front Immunol. 2021;12:667875. doi:10.3389/fimmu.2021.667875
   PubMed Web of Science ®Google Scholar
• Paval DR, Patton R, McDonald J, et al. A systematic review examining the relationship between cytokines and cachexia in incurable cancer. J Cachexia Sarcopenia Muscle. 2022;13(2):824–838. doi:10.1002/jcsm.12912
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Andersson Å, Zhu L, et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy. 2012;4(3):291–304. doi:10.2217/imt.11.178
   PubMed Web of Science ®Google Scholar
• Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585–590. doi:10.1097/JTO.0b013e3181d60fd7
   PubMed Web of Science ®Google Scholar
• Zaynagetdinov R, Stathopoulos GT, Sherrill TP, et al. Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytes. Oncogene. 2012;31(26):3164–3176. doi:10.1038/onc.2011.480
   PubMed Web of Science ®Google Scholar
• Zdanov S, Mandapathil M, Abu Eid R, et al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunol Res. 2016;4(4):354–365. doi:10.1158/2326-6066.CIR-15-0241
   PubMed Web of Science ®Google Scholar
• Lilis I, Ntaliarda G, Papaleonidopoulos V, et al. Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma. Oncoimmunology. 2019;8(7):1593802. doi:10.1080/2162402X.2019.1593802
   PubMed Web of Science ®Google Scholar
• McLoed AG, Sherrill TP, Cheng DS, et al. Neutrophil-derived IL-1β impairs the efficacy of NF-κB inhibitors against lung cancer. Cell Rep. 2016;16(1):120–132. doi:10.1016/j.celrep.2016.05.085
   PubMed Web of Science ®Google Scholar
• Kim JW, Koh Y, Kim DW, et al. Clinical implications of VEGF, TGF-β1, and IL-1β in patients with advanced non-small cell lung cancer. Cancer Res Treat. 2013;45(4):325–333. doi:10.4143/crt.2013.45.4.325
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–1842. doi:10.1016/S0140-6736(17)32247-X
   PubMed Web of Science ®Google Scholar
• Agalioti T, Giannou AD, Krontira AC, et al. Mutant KRAS promotes malignant pleural effusion formation. Nat Commun. 2017;8(1):15205. doi:10.1038/ncomms15205
   PubMed Web of Science ®Google Scholar
• Marazioti A, Lilis I, Vreka M, et al. Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion. Nat Commun. 2018;9(1):672. doi:10.1038/s41467-018-03051-z
   PubMed Web of Science ®Google Scholar
• Giannou AD, Marazioti A, Spella M, et al. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125(6):2317–2334. doi:10.1172/JCI79840
   PubMed Web of Science ®Google Scholar
• Xi Y, Chen Y. Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis. Cancer Lett. 2014;353(1):8–16. doi:10.1016/j.canlet.2014.07.010
   PubMed Web of Science ®Google Scholar
• Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A, Aaronson SA. Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 2009;28(21):2163–2172. doi:10.1038/onc.2009.82
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329–341. doi:10.1038/nrm2882
   PubMed Web of Science ®Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569–579. doi:10.1038/nrclinonc.2009.130
   PubMed Web of Science ®Google Scholar
• Chinchilla P, Xiao L, Kazanietz MG, Riobo NA. Hedgehog proteins activate pro-angiogenic responses in endothelial cells through non-canonical signaling pathways. Cell Cycle. 2010;9(3):570–579. doi:10.4161/cc.9.3.10591
   PubMed Web of Science ®Google Scholar
• Desai A, Adjei AA. FGFR signaling as a target for lung cancer therapy. J Thorac Oncol. 2016;11(1):9–20. doi:10.1016/j.jtho.2015.08.003
   PubMed Web of Science ®Google Scholar
• Hu H, Chen Y, Tan S, et al. The research progress of antiangiogenic therapy, immune therapy and tumor microenvironment. Front Immunol. 2022;13:802846. doi:10.3389/fimmu.2022.802846
   PubMed Web of Science ®Google Scholar
• Bellone M, Calcinotto A. Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol. 2013;3:231. doi:10.3389/fonc.2013.00231
   PubMedGoogle Scholar
• Markowitz SD, Roberts AB. Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev. 1996;7(1):93–102. doi:10.1016/1359-6101(96)00001-9
   PubMedGoogle Scholar
• Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328(2):198–206. doi:10.1016/j.canlet.2012.09.017
   PubMed Web of Science ®Google Scholar
• Zhao G, Cardenas H, Matei D. Ovarian cancer-why lipids matter. Cancers. 2019;11(12):E1870. doi:10.3390/cancers11121870
   PubMed Web of Science ®Google Scholar